DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant's election with traverse of Group I, Claims 1-17 and 23 in the reply filed on 6/29/2026 is acknowledged. The traversal is on the ground(s) that Claims 18-21 are dependent upon claim 1 and that there would not be a significant search burden. This is not found persuasive because while the composition used in the method of Group II is dependent upon claim 1, the composition could be used as a two part adhesive and similarly, could be used as a surface coating or to form a molded article, which would all represent different products.
The requirement is still deemed proper and is therefore made FINAL.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1, 3-6, and 9 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Moore (US 20150231588).
Regarding Claims 1 and 3-5,
Moore teaches compositions that contain a plurality of microcapsules in an epoxy resin (Abstract) where the core of the microcapsules contains amine compounds such as triethylenetetramine, tetraethylenepentamine, or polyalkyleneoxide polyamines or combinations thereof (Paragraph 34) and where the shell of the capsules is comprised of one or more polyureas (Paragraph 48) which is crosslinked with a polyisocyanate (Paragraph 69).
Regarding Claim 6,
Moore teaches that the polyurea is formed with a polyisocyanate, including bis(4-isocaynatocyclohexyl)methane (Paragraph 69).
Regarding Claim 9,
Moore teaches that the composition contains at least one epoxy monomer (Paragraph 76) and notes the use of an epoxy monomer based upon bisphenol A (Paragraph 91).
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claims 2, 7-8, and 23 are rejected under 35 U.S.C. 103 as being unpatentable over Moore (US 20150231588) as applied to claims 1, 3-6, and 9 above.
Regarding Claim 2,
Moore teaches microcapsules are preferred to be between 5,000 and 50,000 nanometers (5 to 50 microns)(Paragraph 49), which overlaps with the range of the instant claim. It would have been obvious prior to the effective filing date of the instant application to have selected the overlapping portion of the ranges because the selection of overlapping portions of ranges has been held to be a prima facie case of obviousness. See MPEP 2144.05.I.
Regarding Claim 7,
Moore teaches the required amines in regard to claims 1 and 3-5 above and further teaches that combinations of these amines may be used (Paragraph 34). One of ordinary skill in the art would recognize that different amines would impart different characteristics on the cured product or would react at different rates and would be motivated to include more than one amine in order to alter the final characteristics of the cured composition or to alter the rate of the curing reaction. As such, it would have been obvious prior to the effective filing date of the instant application to have used a mixture of amines.
Regarding Claim 8,
Moore teaches that the amines can be used in combination, but does not teach the relative amounts of each amine. However, one of ordinary skill in the art would recognize that different amines would impart different properties, as Moore notes that some of the listed amines contain electron withdrawing groups, or hydrophobic groups (Paragraph 34) which would impart different characteristics. The ordinarily skilled artisan would therefore alter the amine composition in order to alter these characteristics or to improve mixing with the desired epoxy resins in the composition. As such, it would have been obvious prior to the effective filing date of the instant application to have used the combination of amines in any relative amount to afford adhesives with differing physical properties.
Regarding Claim 23,
Moore teaches that the composition is coated onto a surface and can initiate curing through mechanical sheering (Paragraph 7) and that the composition is useful as an adhesive (Paragraph 75). While Moore does not teach a specific use as an adhesive, one of ordinary skill in the art would recognize through Moore’s disclosure of the composition being useful as an adhesive as well as the knowledge that similar compositions known in the art are used as such, it would have been obvious prior to the effective filing date of the instant application to have used the composition as a one-part adhesive.
Claims 10-17 are rejected under 35 U.S.C. 103 as being unpatentable over Moore (US 20150231588) as applied to claims 1-9 and 23 above, and further in view of Hunter (US 20120010329).
Regarding Claims 10-11, 13, and 15,
Moore teaches that the composition uses epoxy resins, but does not specify the use of bisphenol A and bisphenol F epoxy resins together. Hunter teaches curable epoxy resin compositions (Abstract) where epoxy resins include those derived from bisphenol A and bisphenol F, as well as mixtures thereof (Paragraph 37) while using similar amines such as Jeffamines (polyalkyleneoxide polyamines, Paragraph 48) and tetraethylene pentamine (Paragraph 52) to those used by Moore. Hunter further teaches that amines such as tetraethylene pentaamine can be used as adducts with epoxy resins (Paragraph 52) and other hardeners such as polymercaptans and polyamines (Paragraph 70). One of ordinary skill in the art would recognize that Moore broadly teaches the use of epoxy resins but does not teach limitations on the overall composition and would seek out teachings in the prior art such as Hunter for additional guidance on the composition components. As such, it would have been obvious prior to the effective filing date of the instant application to have combined the teachings of Hunter and Moore to obtain the predictable result of a curable epoxy composition with a reasonable expectation of success.
Regarding Claims 12, 14, and 16-17,
Moore in view of Hunter teaches the composition as required by the instant claims as discussed above in regard to claims 1-11 and 13, but does not teach the specific amounts of microcapsules relative to the epoxy resin nor the amount of epoxy resin reacted with polyamine prior to curing. However, the examiner notes that the amount of curing agent (which is contained within the microcapsules) relative to the amount of epoxy resin would affect the curing rate as well as the physical properties of the cured product through structures formed such as interpenetrating networks mentioned by Hunter (Paragraph 54) and as such, the ratio of curing agent to epoxy resin would represent a result-effective variable. Further, as Moore in view of Hunter teaches the use of the required amines as well as the amine adducts of epoxy resins as noted above in regard to claims 1-10 and 13, it would have been obvious prior to the effective filing date of the instant application to have used them in any amount and in any ratio.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ADAM J BERRO whose telephone number is (703)756-1283. The examiner can normally be reached M-F 8:30-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Kelley can be reached at 571-270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/A.J.B./Examiner, Art Unit 1765
/JOHN M COONEY/Primary Examiner, Art Unit 1765